Literature DB >> 17920283

Increased metabolism in the R6/2 mouse model of Huntington's disease.

Jorien M M van der Burg1, Karl Bacos, Nigel I Wood, Andreas Lindqvist, Nils Wierup, Ben Woodman, Jaclyn I Wamsteeker, Ruben Smith, Tomas Deierborg, Michael J Kuhar, Gillian P Bates, Hindrik Mulder, Charlotte Erlanson-Albertsson, A Jennifer Morton, Patrik Brundin, Asa Petersén, Maria Björkqvist.   

Abstract

Huntington's disease (HD) is a hereditary disorder characterized by personality changes, chorea, dementia and weight loss. The cause of this weight loss is unknown. The aim of this study was to examine body weight changes and weight-regulating factors in HD using the R6/2 mouse model as a tool. We found that R6/2 mice started losing weight at 9 weeks of age. Total locomotor activity was unaltered and caloric intake was not decreased until 11 weeks of age, which led us to hypothesize that increased metabolism might underlie the weight loss. Indeed, oxygen consumption in R6/2 mice was elevated from 6 weeks of age, indicative of an increased metabolism. Several organ systems that regulate weight and metabolism, including the hypothalamus, the stomach and adipose tissue displayed abnormalities in R6/2 mice. Together, these data demonstrate that weight loss in R6/2 mice is associated with increased metabolism and changes in several weight-regulating factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17920283     DOI: 10.1016/j.nbd.2007.07.029

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  32 in total

1.  Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.

Authors:  Miriam A Hickey; Chunni Zhu; Vera Medvedeva; Nicholas R Franich; Michael S Levine; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2011-10-20       Impact factor: 4.314

Review 2.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

3.  Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.

Authors:  Danielle A Simmons; Rishi A Mehta; Julie C Lauterborn; Christine M Gall; Gary Lynch
Journal:  Neurobiol Dis       Date:  2010-10-23       Impact factor: 5.996

4.  Mutant huntingtin fragment selectively suppresses Brn-2 POU domain transcription factor to mediate hypothalamic cell dysfunction.

Authors:  Tomoyuki Yamanaka; Asako Tosaki; Haruko Miyazaki; Masaru Kurosawa; Yoshiaki Furukawa; Mizuki Yamada; Nobuyuki Nukina
Journal:  Hum Mol Genet       Date:  2010-02-25       Impact factor: 6.150

Review 5.  Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling.

Authors:  Nickolay Brustovetsky
Journal:  Mol Neurobiol       Date:  2015-05-05       Impact factor: 5.590

Review 6.  Shaping the role of mitochondria in the pathogenesis of Huntington's disease.

Authors:  Veronica Costa; Luca Scorrano
Journal:  EMBO J       Date:  2012-03-23       Impact factor: 11.598

7.  Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.

Authors:  Geraldine T Petr; Laurel A Schultheis; Kayla C Hussey; Yan Sun; Janet M Dubinsky; Chiye Aoki; Paul A Rosenberg
Journal:  Eur J Neurosci       Date:  2013-04-16       Impact factor: 3.386

8.  Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease.

Authors:  Nigel I Wood; Valentina Carta; Stefan Milde; Elizabeth A Skillings; Catherine J McAllister; Y L Mabel Ang; Alasdair Duguid; Nadeev Wijesuriya; Samira Mohd Afzal; Joe X Fernandes; T W Leong; A Jennifer Morton; Jennifer Morton
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

9.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

10.  Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Hilary Moffitt; Graham D McPhail; Ben Woodman; Carl Hobbs; Gillian P Bates
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.